Hélène Lelièvre

The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low <i>Xist</i> Expression

Marion A. Salvador, Julien Wicinski, Olivier Cabaud et al. · Clinical Cancer Research · 2013 · 128 citations

Medicine, Oncology, Pharmacology +17

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, John E. Godwin, Michael P. Rettig et al. · Blood · 2017 · 62 citations

Medicine, Hematology, Oncology +17

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

Franck Morschhauser, Louis Terriou, Bertrand Coiffier et al. · Investigational New Drugs · 2015 · 39 citations

Medicine, Oncology, Pharmacology +13

Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome

Bénédicte Delaval, Sébastien Letard, Hélène Lelièvre et al. · Cancer Research · 2005 · 37 citations

Life Sciences, Cell Biology, Oncology +17

Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts

Mélanie Gressette, Benjamin Vérillaud, Anne-Sophie Jimenez-Pailhès et al. · PLoS ONE · 2014 · 36 citations · Full text

Medicine, Oncology, Pharmacology +11